Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate. Spaglumic acid is a mast cell stabilizer. Thus it is used in allergic conditions such as allergic conjunctivitis. Specifically spaglumic acid is approved in Portugal under the brand name Naabak and in Greece under the brand name Naaxia for use in patients with allergic conjunctivitis. (en)
|
http://linked.open...generalReferences
| - # Sala-Rabanal M, Loo DD, Hirayama BA, Turk E, Wright EM: Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1. J Physiol. 2006 Jul 1;574(Pt 1):149-66. Epub 2006 Apr 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16627568 # Sanchis-Merino ME, Montero JA, Ruiz-Moreno JM, Rodriguez AE, Pastor S: Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis. Exp Eye Res. 2008 May;86(5):791-7. doi: 10.1016/j.exer.2008.02.007. Epub 2008 Mar 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18378229 # Purello D'Ambrosio F, Gangemi S, Ricciardi L, Cuzzocrea S, Di Lorenzo G: Lodoxamide versus spaglumic acid: a comparative double-blind trial on patients suffering from seasonal allergic conjunctivitis induced by Parietaria pollen. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):233-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9395007 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...ugbank/indication
| - Used in patients with allergic conjunctivitis. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Spaglumic acid is a mast cell stabilizer. Mast cells are involved in producing an allergic response by releasing inflammatory mediators such as histamine. Mast cell stablizers block the release of histamine and other mediators by inhibiting mast cell degranulation, which is the process of releasing these mediators. Inhibition occurs through inhibition of specific calcium channels to stabilize the mast cell and prevent degranulation. (en)
|
http://linked.open.../drugbank/synonym
| - N-(N-Acetyl-l-β-aspartyl)-l-glutamic acid (en)
- N-Acetyl-l-aspartylglutamate (en)
- N-Acetylaspartylglutamic acid (en)
- NAAG (en)
|
http://linked.open...k/foodInteraction
| - No food effects were found. (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...ynthesisReference
| - Reddy AV, Ravindranath B: Synthesis of alpha-, beta- and cyclic spaglumic acids. Int J Pept Protein Res. 1992 Nov;40(5):472-6. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |